&nbsp;

CART-cellTherapyforPediatricRelapsedRefractoryB-cellALL.pdf

Dec 1969

Statistical Reports

Rapport sur le rendement du dépistage du cancer en Ontario 2023

Jan 2024

Document

FITKitInstructions-Slovak.pdf

Dec 1969

Document

FITKitInstructions-Dari.pdf

Dec 1969

Document

FITKitInstructions-Pashto.pdf

Dec 1969

Regimen

BORTDEXALENA(LD)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - In Combination with Lenalidomide and Dexamethasone for Previously Untreated Multiple Myeloma Pre-SCT

ODB Limited Use

lenalidomide - Induction therapy for transplant eligible, newly diagnosed multiple myeloma, according to clinical criteria

ODB - General Benefit

dexamethasone

Drugs Used:

Quick Link(s):

Regimen Monograph

Regimen

MOGA

Cancer Type:

Hematologic,

Lymphoma - T-cell

Intent: Palliative

Funding:

New Drug Funding Program

Mogamulizumab - Relapsed or Refractory Mycosis Fungoides or Sezary Syndrome

Drugs Used:

mogamulizumab

Quick Link(s):

Regimen Monograph

Regimen

IBRUVENE

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - For the treatment of patients with chronic lymphocytic leukemia (CLL), in combination with venetoclax, based on criteria

Exceptional Access Program

venetoclax - For the treatment of patients with chronic lymphocytic leukemia (CLL), in combination with ibrutinib, based on criteria

Drugs Used:

iBRUtinib,

venetoclax

Quick Link(s):

Regimen Monograph

Regimen

DOST(MNT); CRBPPACL+DOST

Cancer Type:

Gynecologic,

Endometrial

Intent: Adjuvant, Curative, Palliative

Funding:

New Drug Funding Program

Dostarlimab - Primary Advanced or Recurrent MSI-H or dMMR Endometrial Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Regimen

CARFDEXASELI

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

dexamethasone

Drugs Used:

carfilzomib (Unfunded),

dexamethasone,

selinexor (Unfunded)

Quick Link(s):

Regimen Monograph

Mar 2024

Regimen

EPCO; EPCO(RAMP)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Palliative

Funding:

New Drug Funding Program

Epcoritamab (Outpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma

High Cost Therapy Funding Program

Epcoritamab (Inpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Drugs Used:

epcoritamab

Quick Link(s):

Regimen Monograph

Regimen

GLOF; GLOF(RAMP)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Palliative

Funding:

New Drug Funding Program

Glofitamab (Outpatient) - Relapsed or Refractory Diffuse Large B-cell Lymphoma

High Cost Therapy Funding Program

Glofitamab (Inpatient) - Relapsed or Refractory Diffuse Large B-cell Lymphoma

Drugs Used:

oBINutuzumab,

glofitamab